Siemens Healthineers Receives Six FDA Clearances and Eyes a 2027 Spin-Off, But Downgrades and China Woes Keep Shares Near Lows

Despite cutting-edge AI imaging and plans to separate from parent Siemens, Healthineers shares hover near a 52-week low, dragged by weak diagnostics and China headwinds.

Siemens Healthineers finds itself in an uncomfortable spot: the stock is clinging to its 52-week low, yet the company is simultaneously rolling out cutting-edge AI imaging systems, preparing to shed non-core assets, and advancing plans for a full separation from parent Siemens. The contradiction has left investors torn between near-term headwinds and longer-term strategic shifts.

On Friday, shares closed at €33.59, a 1.35% decline that left the stock just 0.27% above its 12-month trough. The year-to-date decline stands at 24.41%, and over the past twelve months the stock has shed 31.21%. The slide reflects a stark divergence within the group’s portfolio: while Imaging and the cancer specialist Varian delivered solid growth in the second quarter, the Diagnostics segment has been a persistent drag, posting an operating margin of only 0.9% in its latest showing. A soft Chinese market, weighed down by lower reimbursement rates and volume-based procurement, has compounded the pressure, leading management to trim its full-year revenue guidance. Group revenue for the last reported quarter slipped to just under €5.7 billion, with earnings per share also moving lower.

Two major analysts responded to the deteriorating picture. Jefferies slashed its price target from €60 to €50, though it maintained a buy recommendation. Deutsche Bank Research took a more cautious view, cutting its fair value to €38 with a hold rating, noting that the targets for the current fiscal year look increasingly ambitious given the slowdown in China and diagnostics.

But the company is not standing still. The planned spin-off of Siemens Healthineers from its parent, first flagged last year, is on track for a shareholder vote at the annual general meeting in February 2027. Siemens currently holds roughly 67% of the shares and intends to transfer nearly half of that stake directly to its own shareholders, reducing its holding to around 37% in the first step. Over the long term, the industrial conglomerate aims to shrink its position to below 20% and treat the remainder as a financial investment. While Moody’s has assigned a solid A3 rating to the medical technology group — despite net debt rising above €13 billion — final tax clearance from the authorities for a tax-neutral transaction is still pending.

In parallel, Siemens Healthineers is streamlining its portfolio. The company is reportedly preparing to sell its Indian cancer clinic chain, American Oncology Institute, in a deal valued at roughly 1.5 to 2 billion Indian rupees. Private-equity funds and specialized healthcare providers are said to be among the interested parties. The move aligns with management’s strategy to shed capital-intensive service businesses and concentrate on higher-margin, technology-driven areas such as imaging and robotic surgery.

Regulatory wins have also provided ammunition for the bull case. The U.S. Food and Drug Administration cleared six new Artis systems for interventional imaging, all equipped with the Optiq-AI imaging chain that uses deep learning to reduce image noise. The systems allow for better image quality at lower radiation doses — a selling point that could help win orders in cost-constrained hospitals. Separately, the Atellica testosterone assay received renewed certification from the U.S. Centers for Disease Control and Prevention, a stamp of reliability in a Diagnostics unit that urgently needs to restore credibility.

The next major test comes within days. Two specialist conferences — the ESTRO congress in Stockholm, focused on radiation oncology, and the EuroPCR meeting in Paris for interventional cardiology — will give Siemens Healthineers a platform to showcase its latest offerings. For the market, the key question is whether these events will generate concrete pipeline signals for Imaging and Advanced Therapies, the segments that must compensate for Diagnostics and China weakness.

Without tangible improvement from those two trouble spots, the stock will remain vulnerable near its lows. But should the profit engines in Imaging and Varian regain momentum, the focus could quickly shift back to earnings per share in the range of €2.20 to €2.30, providing a floor for valuation. For now, Siemens Healthineers is playing both defense and offense simultaneously — and the market is waiting to see which side wins.